Parastou Foroutan1,
Jenny M. Kreahling2, Damon Reed2, 3, Mark C.
Lloyd4, Soner Altiok2, 3, Gary V. Martinez1,
Robert J. Gillies1
1Imaging,
H. Lee Moffitt Cancer Center, Tampa, FL, United States; 2Experimental
Therapeutics Program, H. Lee Moffitt Cancer Center, Tampa, FL, United States;
3The Sarcoma Program, H. Lee Moffitt Cancer Center, Tampa, FL,
United States; 4Analytic Microscopy, H. Lee Moffitt Cancer Center,
Tampa, FL, United States
MRI at 7T was employed to evaluate the therapeutic effects of MK1775 and gemcitabine (Gem) in patient derived xenograft mouse models for osteosarcoma. ROI analysis showed significantly smaller tumor volumes for the treated animals compared to controls, particularly the Gem and Combination (Comb) groups. Significant increases in mean ADC for these groups were observed immediately following the first treatment, which also correlated with changes in skewness and kurtosis. Histology also showed significantly higher apoptosis and DNA damage in Comb and while tumor volume correlated well with these insults, changes in ADC indicating treatment response occured at earlier time points.